Biopharmaceutical Company-Zydus Launches the World’s First Biosimilar of Nivolumab in India to Treat Multiple Cancers
DSIJ Intelligence-1Categories: Mindshare, Trending
As of September 30, 2025, the group employs 29,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives.
Zydus Lifesciences has marked a significant milestone in oncology by launching Tishtha™, the world’s first biosimilar of Nivolumab, in the Indian market. This immunotherapy drug is designed to treat several types of cancer by targeting specific proteins to help the immune system recognise and attack cancer cells. By introducing this biologic in 100 mg and 40 mg dosages, Zydus aims to provide oncologists with more precise dosing options, which helps minimise medicinal wastage and improves the overall economic efficiency of long-term cancer care.
The launch is poised to benefit over 5 lakh patients by dramatically lowering the financial barriers to advanced treatment. Priced at approximately one-fourth the cost of the original reference drug, Tishtha™ addresses the critical challenges of affordability and consistent supply within India’s healthcare landscape. Because checkpoint inhibitors often require multiple cycles of therapy, this locally manufactured biosimilar ensures that patients can maintain their treatment schedules without the clinical or financial stress caused by high costs or import-related supply interruptions.
Speaking on the development, Dr Sharvil P. Patel, Managing Director, Zydus Lifesciences Ltd., said, “At Zydus, we believe every patient deserves timely access to affordable, advanced cancer care. With the launch of Tishtha™, we are expanding access to Immuno-Oncology through a patient-centric therapy. Our aim is to support patients with consistent care throughout their treatment journey. We remain committed to improving patient access to high-quality biosimilar immunotherapies.”
About Zydus Lifesciences Limited
Zydus Lifesciences Limited is an innovation-led life-sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a global footprint across the United States, India and other international markets. As of September 30, 2025, the group employs 29,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries.
Disclaimer: The article is for informational purposes only and not investment advice.